Fortress Biotech, Inc. FBIO

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
56/100
Moderate

Ranked against 712 peers in Biotechnology

About Fortress Biotech, Inc.

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions … Full FBIO analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.85), suggesting sticky customer base.
  • Cash Generation Consistent Cash generation is consistent (score 0.70), indicating reliable business model.

Key risks

  • Liquidity Concerns Liquidity is concerning (score 0.29), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
49
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where FBIO ranks in Biotechnology

Fortress Biotech, Inc. ranks #155 of 713 scored companies in Biotechnology by moat score — the top 22%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
151 CERo Therapeutics Holdings, Inc. CEROW 57/100 Moderate
152 Nurix Therapeutics, Inc. NRIX 57/100 Moderate
153 AbCellera Biologics Inc. ABCL 57/100 Moderate
154 Fortress Biotech, Inc. - 9.375% FBIOP 57/100 Moderate
155 Fortress Biotech, Inc. FBIO 56/100 Moderate
156 Telix Pharmaceuticals Limited TLX 56/100 Moderate
157 Rein Therapeutics, Inc. RNTX 56/100 Moderate
158 Artelo Biosciences, Inc. ARTL 56/100 Moderate
159 Serina Therapeutics, Inc. SER 56/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How FBIO scores on the Corporate Default defenses

Pricing Power

Score 49 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 64 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 76 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 35 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 65 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 55 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding FBIO's moat

What is Fortress Biotech, Inc.'s moat score?

Fortress Biotech, Inc. (FBIO) scores 56 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #155 of 713 scored companies in Biotechnology, the top 22%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (76/100) and its weakest is Capital Efficiency (35/100).

How does Fortress Biotech, Inc. compare with other Biotechnology companies?

Fortress Biotech, Inc. ranks #155 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Fortress Biotech, Inc. - 9.375% (FBIOP) at 56 just above it and Telix Pharmaceuticals Limited (TLX) at 56 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Fortress Biotech, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Fortress Biotech, Inc.?

The Corporate Default template measures 6 defenses, and FBIO scores: Pricing Power (49), Cost Advantage (64), Customer Stickiness (76), Capital Efficiency (35), Resilience (65), Scale & Market Position (55). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000